Olaparib and somatic BRCA mutations

類似資料

• Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
  著者:: Rafii, Saeed, 等
  出版事項: (2017)
• Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
  著者:: Dougherty, Brian A., 等
  出版事項: (2017)
• Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
  著者:: Schwartzberg, Lee S., 等
  出版事項: (2021)
• Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
  著者:: Golan, Talia, 等
  出版事項: (2019)
• Metastatic Breast Cancer with BRCA Mutation Discovered By Next-Generation Sequencing Responding to Olaparib
  著者:: Rizvi, Wajeeha, 等
  出版事項: (2017)